AUTHORS
Stella Lee, BS, David Dong2, Callan Rose Bateman, N/A3, Charles Hsu, MD4, Jian-Ming Li, MD PhD5, Ned K. Waller, MD PhD FACP6
AFFILIATIONS
1 Emory College of Arts and Sciences, Atlanta, Georgia, United States
2 Emory College of Arts and Sciences, Atlanta, Georgia, United States
3 Westminster Schools of Atlanta, Atlanta, Georgia, United States
4 Winship Cancer Institute, Atlanta, Georgia, United States
5 Winship Cancer Institute, Atlanta, Georgia, United States
6 Winship Cancer Institute, Atlanta, Georgia, United States
ABSTRACT
Introduction: Acute myeloid leukemia (AML) remains difficult to treat, and immune checkpoint blockade has shown limited efficacy compared with solid tumors. Vasoactive intestinal peptide (VIP) is an immunosuppressive neuropeptide that inhibits T-cell activation, making VIP receptor blockade a potential strategy to enhance anti-tumor immunity. We hypothesized that combining adoptive T-cell transfer with immune checkpoint blockade, including VIP receptor antagonism, would further improve anti-leukemia efficacy.
Methods: Two murine myeloid neoplasm models were studied. C57BL/6 mice received intravenous C1498 leukemia cells (1×106), and DBA/2J mice received subcutaneous P815 mastocytoma cells (1×105). Tumor-bearing mice (n=10/group) were randomized to treatment. P815-bearing mice received control, CAMV-01 (6 nmol weekly), anti-PD-1 (200 μg twice weekly), or both agents. In a separate experiment, mice received control, CAMV-01 (6 nmol twice weekly), or CAMV-01 plus adoptive transfer of 1×106 memory T cells from mice that had eradicated leukemia following CAMV-01 treatment. C1498-bearing mice received control, naïve T-cell transfer, CAMV-01 plus anti-PD-1, or CAMV-01 plus anti-PD-1 with naïve T-cell transfer. Therapy began 7 days after tumor inoculation and continued for 2 weeks. Peripheral blood was analyzed by multiparameter flow cytometry to assess T-cell activation, differentiation, and checkpoint expression.
Results: In the P815 model, CAMV-01 plus anti-PD-1 produced greater survival than either monotherapy. By day 29, all control mice had died, whereas 60% of combination-treated mice remained alive through day 60 (p<0.0001), compared with 20% receiving anti-PD-1 alone and 10% receiving CAMV-01 alone. CAMV- 01 combined with memory T-cell transfer resulted in 40% survival and prolonged median survival from 25 to 45 days. Baseline tumor volumes were comparable across groups (55.3±3.8 mm³). Combination therapy of immune check-point blockade with memory T cells achieved the greatest tumor control, with 75% relative reduction in tumor-volume compared with 66% for memory T-cell transfer alone and 40% for CAMV-01 alone. CAMV-01 alone, memory T-cell transfer alone, and combination therapy reduced circulating PD-1+ CD4+ memory T cells by 44%, 40%, and 70%, respectively. Memory T-cell transfer alone also increased CD4+ and CD8+ effector-memory T cells 8-fold and 4-fold, respectively, versus controls. In the C1498 model, CAMV-01 plus anti-PD-1 with or without naïve T-cell transfer produced only modest survival benefit. By day 29 all control mice had died, whereas 20% of mice receiving naïve T-cell transfer alone or combined therapy survived; CAMV-01 plus anti-PD-1 alone produced 10% survival. Drug treatment increased activated CD4+ and CD8+ T cells by 64% relative to controls, while naïve T-cell transfer alone increased activation by 40%. Unexpectedly, combining naïve T-cell transfer with CAMV-01 plus anti-PD-1 reduced activated T-cell frequencies by 62% compared with either treatment alone.
Conclusions: The efficacy of adoptive T-cell therapy depended on the differentiation state and antigen experience of transferred cells. Naïve T-cell transfer provided minimal therapeutic benefit in the C1498 model and attenuated treatment-associated T-cell activation, suggesting competition with endogenous tumor-reactive T cells for activation or homeostatic signals. In contrast, adoptive transfer of tumor-experienced memory T cells significantly improved survival and tumor control in the P815 model, while reducing PD-1+ memory T cells and expanding effector-memory populations. Although combination therapy increased exhaustion-marker expression relative to memory-cell transfer alone, it produced the greatest tumor regression, consistent with a more robust and sustained anti-tumor immune response. These findings support combining VIP receptor blockade with adoptive transfer of tumor-reactive memory T cells as a promising immunotherapeutic strategy for AML.
DISCLOSURES
Stella Lee, BS: No relevant conflicts of interest to declare.